Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 28, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan...
September 05, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference

NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan...
August 14, 2018 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan...
August 13, 2018 06:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces that FDA Accepts ELZONRIS™ Biologics License Application (BLA) and Grants Priority Review

Conference call on BLA acceptance and commercial readiness scheduled for Monday, August 13, 2018 at 8:30 AM ET NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:...
August 09, 2018 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Second Quarter 2018 Financial Results

NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today its...
June 25, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS™ (tagraxofusp; SL-401) for the Treatment of BPDCN

NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that it has...
June 18, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Positive Clinical Data from ELZONRISTM (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress

NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...
June 15, 2018 08:15 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Presentation of ELZONRIS™ (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress

NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...
June 14, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Three ELZONRIS™ (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress

NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced that ELZONRISTM...
June 05, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO

NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...